Printer Friendly

The bottom line: data from recent industry financial reports. Dollar amounts in millions.

The Bottom Line

Data from recent industry financial reports. Dollar amounts in millions.

Company                        Period   Ended    Sales     Chg.

Agilent Techs. (Bio-             2Q     31-Jul   $500.0    19.0%
  Analytical Msmt.)
Bio-Rad Laboratories             2Q     30-Jun   $339.1     6.7%
Bio-Rad Lab. (Life Science)      2Q     30-Jun   $146.0     8.6%
Bio-Rad Lab. (Clinical           2Q     30-Jun   $189.8     5.3%
  Diagnostics)
Bruker BioSciences               2Q     30-Jun   $121.7    21.1%
Bruker BioSciences (AXS)         2Q     30-Jun    $53.3    36.3%
Bruker BioSciences               2Q     30-Jun    $40.6     2.0%
  (Daltonics)
Bruker BioSciences (Optics)      2Q     30-Jun    $30.3    28.5%
Dionex                           4Q     30-Jun    $86.0    14.3%
Dionex                          FYE     30-Jun   $327.3    12.4%
Harvard Bioscience               2Q     30-Jun    $20.4    12.2%
ICx Technologies                FYE     31-Dec    $90.2   187.1%
ICx Technologies                 1Q     30-Jun    $27.0    38.0%
Invitrogen                       2Q     30-Jun   $321.7    12.7%
Invitrogen (BioDiscovery)        2Q     30-Jun   $222.8     9.9%
Invitrogen (Cell Culture         20     30-Jun    $98.9    19.8%
  Systems)
QIAGEN NV                        2Q     30-Jun   $135.0    19.3%
SEQUENOM                         2Q     30-Jun    $10.2    41.2%
Strategic Diagnostics            2Q     30-Jun     $6.7    19.2%
VWR Int'l                        2Q     29-Jun   $856.2     5.1%
VWR Int'l (No. American Lab)     2Q     29-Jun   $502.3     0.4%
VWR Int'l (European Lab)         2Q     29-Jun   $316.8    14.1%
VWR Int'l Science Educ.          2Q     29-Jun    $37.1     0.0%

Company                        Op. Prof.    Chg.    Net Prof.    Chg.

Agilent Techs. (Bio-              $92.0     39.4%         N/A      N/A
  Analytical Msmt.)
Bio-Rad Laboratories              $35.7    -17.4%     $25.70    -20.4%
Bio-Rad Lab. (Life Science)          N/A      N/A         N/A      N/A
Bio-Rad Lab. (Clinical               N/A      N/A         N/A      N/A
  Diagnostics)
Bruker BioSciences                 $7.0    144.6%      $5.00     95.6%
Bruker BioSciences (AXS)           $4.0    151.7%         N/A      N/A
Bruker BioSciences                ($1.2)       NM         N/A      N/A
(Daltonics)
Bruker BioSciences (Optics)        $5.3    218.5%         N/A      N/A
Dionex                            $19.1     59.0%     $11.90    119.6%
Dionex                            $70.0     25.4%     $45.30     27.0%
Harvard Bioscience                 $2.6     11.6%     ($1.80)       NM
ICx Technologies                ($113.1)       NM   ($127.50)       NM
ICx Technologies                 ($10.2)       NM     ($9.50)       NM
Invitrogen                        $39.0     53.5%     $40.90    113.2%
Invitrogen (BioDiscovery)         $57.3      8.4%         N/A      N/A
Invitrogen (Cell Culture          $20.1     28.8%         N/A      N/A
  Systems)
QIAGEN NV                         $31.0     42.9%     $22.60     59.6%
SEQUENOM                          ($5.2)       NM     ($4.80)       NM
Strategic Diagnostics              $0.2        NM      $0.20        NM
VWR Int'l                          $4.6    -89.9%     $41.30    -21.5%
VWR Int'l (No. American Lab)     ($17.6)       NM         N/A      N/A
VWR Int'l (European Lab)          $18.9     31.3%         N/A      N/A
VWR Int'l Science Educ.            $3.3    -15.4%         N/A      N/A

N/A=not available

NM=not meaningful
COPYRIGHT 2007 Strategic Directions International Inc. (SDI)
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Instrument Business Outlook
Article Type:Financial report
Geographic Code:1USA
Date:Aug 15, 2007
Words:465
Previous Article:Market profile: mass spectrometry and sports doping.
Next Article:OECD releases China innovation review.
Topics:


Related Articles
The Bottom Line.
The Bottom Line.
The Bottom Line.
The Bottom Line.
The Bottom Line.
The Bottom Line.
The bottom line.
The bottom line: data from recent industry financial reports. Dollar amounts in millions.
The bottom line.
The bottom line.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters